| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-07-27 | Antitope (UK) University of North Carolina at Chapel Hill (USA) | monoclonal therapeutic antibodies for the treatment of cancer | cancer | R&D |
Cancer Oncology | R&D agreement |
| 2011-07-26 | arGEN-X (The Netherlands – Belgium) BioWa (Japan) | POTELLIGENT® Technology | licensing |
Licensing agreement | ||
| 2011-07-26 | Selexis (Switzerland) CSL (Australia) | undisclosed therapeutic antibody | services |
Production agreement | ||
| 2011-07-25 | AbD Serotec unit - MorphoSys AG (Germany) Dana-Farber Cancer Institute (USA) | R&D |
Infectious diseases | R&D agreement | ||
| 2011-07-21 | Redbiotech (Switzerland) undisclosed pharmaceutical company | viral protein complex using the rePAX™ technology | manufacturing |
Production agreement | ||
| 2011-07-19 | CEL-SCI Corporation (USA) Teva Pharmaceutical (Israel) | Multikine® | head and neck cancer | Licensing |
Cancer - Oncology | Licensing agreement |
| 2011-07-19 | Lonza (Switzerland) Immune Pharmaceuticals (Israel-USA) | bertilimumab | eosinophilic inflammatory bowel diseases–Crohn’s Disease and Ulcerative Colitis- and eosinophilic gastro-intestinal diseases | manufacturing |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Production agreement |
| 2011-07-19 | to-BBB (The Netherlands) Emultech (The Netherlands) | novel drug candidates | undisclosed untreated CNS diseases | development |
CNS diseases | Development agreement |
| 2011-07-14 | Protagen (Germany) Vela Laboratories (Austria) | comparative biology services | collaboration |
Collaboration agreement | ||
| 2011-07-14 | ALK (Denmark) AllerQuest (USA) | diagnostic product for penicillin allergy | development |
Allergic diseases - Immunological diseases | Development agreement | |
| 2011-07-14 | Angel Biotechnology (UK) BioProcess Technology Consultants (USA) | marketing assistancy for cGMP cell therapy manufacturing | consultancy |
Services contract | ||
| 2011-07-13 | Pfizer (USA - NY) Roslin Cells Ltd (UK) | Stem cells | evaluation |
R&D agreement | ||
| 2011-07-12 | Transgene (France) Vivalis (France) | EB66® cell line | licensing |
Cancer - Oncology - Infectious diseases | Licensing agreement | |
| 2011-07-12 | Roche NimbleGen (Switzerland) Caliper Life Sciences (USA) | development |
Development agreement | |||
| 2011-07-12 | Ipsen (France) Institut Gustave Roussy - IGR (France) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2011-07-11 | Micromet (USA-Germany) Amgen (USA - CA) | BiTE® antibodies against three undisclosed solid tumor targets | solid tumors | R&D |
Cancer - Oncology | R&D agreement |
| 2011-07-07 | Evotec (Germany) UCB (Belgium) | small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders | R&D |
CNS diseases | R&D agreement | |
| 2011-07-05 | Octoplus (The Netherlands) undisclosed Danish pharmaceutical company | microsphere-based formulation | undisclosed | sevelopment |
undisclosed | Development agreement |
| 2011-07-05 | Amgen (USA) NASA (USA) UCB (Belgium) | sclerostin antibody | loss of bone associated with space flight | R&D |
Bone diseases | R&D agreement |
| 2011-07-05 | ReNeuron (UK) Angel Biotechnology (UK) | ReN001 | stroke | manufacturing production |
Cerebrovascular diseases |
